EML4-ALK fusion
A study presented at the AACR meeting showed that Resolution's ctDx-Lung assay reported more oncogenic fusions than Guardant360 in NSCLC patients.
ArcherDx Joins Canadian Personalized Oncology Consortium
The gene fusion assay maker is the sixth member to join the consortium, which also includes Illumina and several pharmaceutical companies.
Pfizer's Xalkori yielded significantly longer progression-free survival than standard chemotherapy in the Phase III trial of first-line treatment of ALK-positive NSCLC.
Using NanoString's nCounter technology, researchers from Pfizer and Seoul National University have developed an ALK test they hope will be as accurate as the gold standard fluorescence in situ hybridization test for identifying patients who could benefit from Pfizer's Xa
Pfizer Submits Crizotinib NDA with FDA; Abbott to File Companion Dx Approval Application Soon
Premium
Pfizer completed submission of its NDA for the ALK-inhibiting non-small cell lung cancer drug crizotinib, and was granted a priority review from the FDA. Meantime, Abbott Molecular plans to submit "shortly" a premarket approval application for a commercial companion diagnostic that will pick out best responders to crizotinib.
Jun 30, 2010